Melinda L. Telli, M.D.
Key Documents
Contact Information
-
Clinical Offices
Stanford Women's Cancer Center 900 Blake Wilbur Dr, 1st Floor Palo Alto, CA 94304 Tel Work (650) 498-6004 Fax (650) 725-9113
- Academic Offices
Alternate Contact Rochelle Wallach Tel Work 650-725-8738Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Breast Cancer
- Breast Cancer - Medical Oncology
- Triple-negative breast cancer
- Locally advanced breast cancer
- Medical Oncology
Administrative Appointments
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology (2010 - 2013)
- Program Committee, ASCO Breast Cancer Symposium (2010 - 2013)
Honors and Awards
- Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010)
- Young Investigator Award, American Society of Clinical Oncology (2009)
- Fellowship Award, Susan G. Komen for the Cure (2008)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2008) |
| B.A.: | University of Pennsylvania, Biology, with Distinction (1996) |
| M.D.: | George Washington University, Medicine, with Distinction (2002) |
| Residency: | Stanford University, Internal Medicine (2005) |
| Fellowship: | Stanford University, Medical Oncology (2008) |
Community and International Work
Internet Links
Scientific Focus
Current Research Interests
My research focuses on breast cancer treatment and survivorship. My primary research interest is the development of novel strategies for the treatment of early stage triple-negative breast cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
Clinical Trials
- Phase II Gemcitabine + Carboplatin + PARP Inhibitor BSI-201 (Iniparib) in Neoadjuvant Tx Breast CA Recruiting
- Phase II Veliparib or Placebo +/- Temozolomide or (Carboplatin & Paclitaxel) in Metastatic Breast CA Recruiting
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Recruiting
- Management of Insomnia in Breast Cancer Patients Recruiting
- Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT Recruiting
Publications
- Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? J Clin Oncol. 2012
- Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; (2): 471-8
- PARP inhibitors in cancer: moving beyond BRCA. Lancet Oncol. 2011; (9): 827-8
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010; (20): 1644-50
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008; (9): 1613-8
Help